Ronald J. Daniels
Known title: DirectorCIK: 0001164475
Ronald J. Daniels's purchase track record
Ronald J. Daniels has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/28/2021 | BBIO | $299K | -19.1% | -35.2% | -20.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| BBIO | ▲ Buy | Grant | 3,990 | $0 | 6/22/2026 | View on chart |
| BBIO | ▲ Buy | Option Exercise | 61,031 | $2.1M | 11/6/2025 | View on chart |
| BBIO | ▼ Sell | Open Market | 61,031 | $3.9M | 11/6/2025 | View on chart |
| BBIO | ▲ Buy | Grant | 6,589 | $0 | 6/20/2025 | View on chart |
| BBIO | ▲ Buy | Open Market | 10,402 | $149K | 12/30/2021 | View on chart |
| BBIO | ▲ Buy | Open Market | 11,745 | $150K | 12/28/2021 | View on chart |
| BBIO | ▼ Sell | Open Market | 11,745 | $150K | 12/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BridgeBio Reports Inducement Grants and Phase 3 Encaleret Success
BridgeBio Pharma announced it has received inducement grants under Nasdaq Rule 5635(c)(4) and released new data from its Phase 3 CALIBRATE trial for Encaleret. The study showed a 100% improvement in at least one ADH1 symptom and increased bone turnover compared with standard care. Additional real‑world data for Acoramidis demonstrated lower composite risk versus Tafamidis in ATTR‑CM patients. These results support the company’s therapeutic pipeline and may influence investor perception.
BridgeBio Reports Inducement Grants and Phase 3 Encaleret Success. BridgeBio Pharma announced it has received inducement grants under Nasdaq Rule 5635(c)(4) and released new data from its Phase 3 CALIBRATE trial for Encaleret. The study showed a 100% improvement in at least one ADH1 symptom and increased bone turnover compared with standard care. Additional real‑world data for Acoramidis demonstrated lower composite risk versus Tafamidis in ATTR‑CM patients. These results support the company’s therapeutic pipeline and may influence investor perception.